These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 24237999)

  • 1. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience.
    Cannon GW; Wang BC; Park GS; Koenig A; Collier DH; Keystone EC
    Clin Exp Rheumatol; 2013; 31(6):919-25. PubMed ID: 24237999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis.
    van der Heijde D; Klareskog L; Landewé R; Bruyn GA; Cantagrel A; Durez P; Herrero-Beaumont G; Molad Y; Codreanu C; Valentini G; Zahora R; Pedersen R; MacPeek D; Wajdula J; Fatenejad S
    Arthritis Rheum; 2007 Dec; 56(12):3928-39. PubMed ID: 18050208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
    Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries.
    Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; McCroskery P; Baumgartner SW; Markenson JA
    J Rheumatol; 2011 Jan; 38(1):21-8. PubMed ID: 20952478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E; Freundlich B; Schiff M; Li J; Hooper M
    J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
    Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
    Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.
    Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK;
    J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
    van der Heijde D; Klareskog L; Singh A; Tornero J; Melo-Gomes J; Codreanu C; Pedersen R; Freundlich B; Fatenejad S
    Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results.
    van der Heijde D; Klareskog L; Boers M; Landewé R; Codreanu C; Bolosiu HD; Pedersen R; Fatenejad S;
    Ann Rheum Dis; 2005 Nov; 64(11):1582-7. PubMed ID: 15860509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.
    Landewé R; van der Heijde D; Klareskog L; van Vollenhoven R; Fatenejad S
    Arthritis Rheum; 2006 Oct; 54(10):3119-25. PubMed ID: 17009230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
    Klareskog L; van der Heijde D; de Jager JP; Gough A; Kalden J; Malaise M; Martín Mola E; Pavelka K; Sany J; Settas L; Wajdula J; Pedersen R; Fatenejad S; Sanda M;
    Lancet; 2004 Feb; 363(9410):675-81. PubMed ID: 15001324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial.
    Curtis JR; Yang S; Chen L; Park GS; Bitman B; Wang B; Navarro-Millan I; Kavanaugh A
    Ann Rheum Dis; 2012 Feb; 71(2):206-12. PubMed ID: 21998118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.
    Kobelt G
    Value Health; 2014 Jul; 17(5):537-44. PubMed ID: 25128046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.